You are here

Phase III Trial Evaluates New Irinotecan Formulation in Colorectal Cancer

Goal is progression-free survival (Feb. 28)

A pivotal phase III clinical trial is evaluating HA-Irinotecan (Alchemia Limited) for the treatment of metastatic colorectal cancer in a total of 415 patients in Europe and Australia.

HA-Irinotecan is a new formulation of irinotecan that targets the drug to the tumor, thereby enabling irinotecan to be retained at the tumor site for a longer period and allowing more of the drug to be internalized by the cancer cells. In a phase II trial of HA-Irinotecan in metastatic colorectal cancer, the new formulation achieved a statistically significant increase in progression-free survival (PFS) compared with irinotecan (5.2 months vs. 2.4 months, respectively; P = 0.017), with no increase in toxicity.

The FDA has indicated that successful completion of the new phase III trial may be sufficient for the registration of HA-Irinotecan in the U.S.

The double-blind study is being conducted in second- and third-line colorectal cancer patients. The study’s primary objective is to demonstrate an increase in PFS without increasing treatment toxicity.

Source: Alchemia Limited; February 28, 2013.

Recent Headlines

NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Attacks Cancerous Cells, Leaves Healthy Tissues Alone
Moderates Pre-diabetes Progression, Reduces Cholesterol Levels